DK1113816T3 - Influenzavirus-vaccinesammensætning - Google Patents

Influenzavirus-vaccinesammensætning

Info

Publication number
DK1113816T3
DK1113816T3 DK99944154T DK99944154T DK1113816T3 DK 1113816 T3 DK1113816 T3 DK 1113816T3 DK 99944154 T DK99944154 T DK 99944154T DK 99944154 T DK99944154 T DK 99944154T DK 1113816 T3 DK1113816 T3 DK 1113816T3
Authority
DK
Denmark
Prior art keywords
influenza virus
virus vaccine
vaccine composition
mug
virus antigen
Prior art date
Application number
DK99944154T
Other languages
Danish (da)
English (en)
Inventor
Noel Barrett
Wolfgang Mundt
Friedrich Dorner
Otfried Kistner
Original Assignee
Baxter Healthcare Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=3515932&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1113816(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Baxter Healthcare Sa filed Critical Baxter Healthcare Sa
Application granted granted Critical
Publication of DK1113816T3 publication Critical patent/DK1113816T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DK99944154T 1998-09-15 1999-09-14 Influenzavirus-vaccinesammensætning DK1113816T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
AT0155598A AT408615B (de) 1998-09-15 1998-09-15 Neue influenzavirus-impfstoffzusammensetzung

Publications (1)

Publication Number Publication Date
DK1113816T3 true DK1113816T3 (da) 2006-04-03

Family

ID=3515932

Family Applications (1)

Application Number Title Priority Date Filing Date
DK99944154T DK1113816T3 (da) 1998-09-15 1999-09-14 Influenzavirus-vaccinesammensætning

Country Status (12)

Country Link
US (1) US6372223B1 (fr)
EP (1) EP1113816B1 (fr)
JP (1) JP2003523310A (fr)
AT (2) AT408615B (fr)
AU (1) AU763210B2 (fr)
DE (1) DE59913046D1 (fr)
DK (1) DK1113816T3 (fr)
ES (1) ES2257072T3 (fr)
HK (1) HK1038507A1 (fr)
HU (1) HUP0103908A3 (fr)
NO (1) NO20011282L (fr)
WO (1) WO2000015251A2 (fr)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT407958B (de) 1999-02-11 2001-07-25 Immuno Ag Inaktivierte influenza-virus-vakzine zur nasalen oder oralen applikation
GB9923176D0 (en) * 1999-09-30 1999-12-01 Smithkline Beecham Biolog Novel composition
ES2327103T3 (es) 2000-09-25 2009-10-26 Polymun Scientific Immunbiologische Forschung Gmbh Vacuna viva de influenzavirus y procedimiento de fabricacion.
CN1253220C (zh) * 2001-06-29 2006-04-26 贝克顿迪肯森公司 通过微管在真皮内输入疫苗和基因治疗剂
IL145926A0 (en) * 2001-10-15 2002-07-25 Mor Research Applic Ltd Peptide epitopes of mimotopes useful in immunomodulation
WO2004067020A1 (fr) * 2003-01-30 2004-08-12 Pohang University Of Science And Technology Composition de vaccins a adn presentant une immunogenicite amelioree
US7588774B2 (en) * 2003-05-12 2009-09-15 Becton, Dickinson And Company Molecules enhancing dermal delivery of influenza vaccines
US20050123550A1 (en) * 2003-05-12 2005-06-09 Laurent Philippe E. Molecules enhancing dermal delivery of influenza vaccines
US7270990B2 (en) 2003-06-20 2007-09-18 Microbix Biosystems, Inc. Virus production
EP1708742A4 (fr) * 2003-12-05 2008-11-05 Becton Dickinson Co Procedes pour ameliorer la reponse immunitaire dans une partie intradermique et composes utilises dans ces procedes
DE202005022108U1 (de) 2004-03-09 2013-11-12 Novartis Vaccines And Diagnostics, Inc. Influenza-Virus-Impfstoffe
US20050220854A1 (en) * 2004-04-01 2005-10-06 Yuh-Fun Maa Apparatus and method for transdermal delivery of influenza vaccine
WO2005103235A1 (fr) * 2004-04-19 2005-11-03 Denka Seiken Co., Ltd. Méthode de production de virus
EP2179744B1 (fr) 2004-09-09 2010-12-01 Novartis Vaccines and Diagnostics GmbH Diminution des risques iatrogènes potentiels associés aux vaccins contre la grippe
US20090004222A1 (en) 2004-11-03 2009-01-01 O'hagan Derek Influenza Vaccination
US20060121055A1 (en) * 2004-12-06 2006-06-08 Becton, Dickinson And Company, Inc. Compositions with enhanced immunogenicity
WO2006100111A1 (fr) * 2005-03-23 2006-09-28 Glaxosmithkline Biologicals S.A. Composition
US11707520B2 (en) 2005-11-03 2023-07-25 Seqirus UK Limited Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture
JP5005700B2 (ja) * 2005-11-04 2012-08-22 ノバルティス ヴァクシンズ アンド ダイアグノスティクス エスアールエル アルミニウムアジュバントに即座に吸着されるインフルエンザワクチン
CA2628424A1 (fr) 2005-11-04 2007-05-10 Novartis Vaccines And Diagnostics S.R.L. Vaccins influenza avec adjuvant comprenant des agents d'induction de cytokines
NZ568211A (en) * 2005-11-04 2011-11-25 Novartis Vaccines & Diagnostic Influenza vaccines including combinations of particulate adjuvants and immunopotentiators
PT2368572T (pt) 2005-11-04 2020-06-16 Seqirus Uk Ltd Vacinas com adjuvante dotadas de antigénios não-virião preparados a partir de vírus da gripe cultivado em cultura celular
GB0522601D0 (en) * 2005-11-04 2005-12-14 Chiron Srl Adjuvanted influenza vaccines and kits
WO2007052061A2 (fr) 2005-11-04 2007-05-10 Novartis Vaccines And Diagnostics Srl Emulsions a tensioactif a phase aqueuse libre pour adjuver des vaccins antigrippaux sous-unitaires
KR20080089663A (ko) 2006-01-27 2008-10-07 노바티스 백신즈 앤드 다이아그노스틱스 게엠베하 운트 콤파니 카게 적혈구응집소 및 기질 단백질을 함유한 인플루엔자 백신
AU2007231027B2 (en) 2006-03-24 2013-10-03 Novartis Influenza Vaccines Marburg Gmbh Storage of influenza vaccines without refrigeration
PT2054431E (pt) 2006-06-09 2011-11-03 Novartis Ag Confórmeros de adesinas bacterianas
EP2043682B1 (fr) 2006-07-17 2014-04-02 GlaxoSmithKline Biologicals S.A. Vaccin anti-grippal
AU2007297178B2 (en) 2006-09-11 2014-07-24 Novartis Ag Making influenza virus vaccines without using eggs
WO2008068631A2 (fr) 2006-12-06 2008-06-12 Novartis Ag Vaccins comprenant un antigène issu de quatre souches du virus grippal
US20100068229A1 (en) * 2007-02-07 2010-03-18 Nicola Gargano Recombinant antigens of human cytomegalovirus (hcmv)
US9452209B2 (en) 2007-04-20 2016-09-27 Glaxosmithkline Biologicals Sa Influenza vaccine
NZ582595A (en) 2007-06-27 2012-07-27 Novartis Ag Low-additive influenza vaccines
GB0818453D0 (en) 2008-10-08 2008-11-12 Novartis Ag Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom
JP5415449B2 (ja) * 2007-12-24 2014-02-12 ノバルティス アーゲー 吸着されたインフルエンザワクチンのためのアッセイ
KR101707569B1 (ko) 2008-08-01 2017-02-16 감마 백신즈 피티와이 리미티드 인플루엔자 백신
CN102307590A (zh) 2009-02-10 2012-01-04 诺华有限公司 具有减少量的角鲨烯的流感疫苗
CA2767392C (fr) 2009-07-06 2017-03-14 Variation Biotechnologies, Inc. Procedes de preparation de vesicules et formulations obtenues a partir de celles-ci
US9907746B2 (en) 2009-07-06 2018-03-06 Variation Biotechnologies, Inc. Methods for preparing vesicles and formulations produced therefrom
CA2776874A1 (fr) 2009-10-09 2011-04-14 Cbio Limited Variantes de la chaperonine en position 10
WO2011063133A1 (fr) 2009-11-18 2011-05-26 Auburn University Immunisation par une faible dose d'antigène afin de maximiser l'immunité par les lymphocytes t auxiliaires de type 1 (th1) contre des maladies
CA2840079C (fr) 2010-07-06 2018-07-03 Variation Biotechnologies Inc. Compositions et methodes pour traiter la grippe
CA2812135A1 (fr) 2010-09-07 2012-03-15 Novartis Ag Tests generiques pour la detection de reovirus de mammiferes
FR2966044B1 (fr) * 2010-10-18 2012-11-02 Sanofi Pasteur Procede de conditionnement d'un vaccin contenant un adjuvant d'aluminium
MX359103B (es) 2011-01-13 2018-09-14 Variation Biotechnologies Inc Composiciones y sus usos en el tratamiento de infecciones virales.
US20130323280A1 (en) 2011-01-13 2013-12-05 Variation Biotechnologies, Inc. Methods for preparing vesicles and formulations produced therefrom
AU2012211043B2 (en) 2011-01-27 2017-04-06 Gamma Vaccines Pty Limited Combination vaccines
US20140328876A1 (en) 2011-11-18 2014-11-06 Variation Biotechnologies Inc. Synthetic derivatives of mpl and uses thereof
WO2013104995A2 (fr) 2012-01-12 2013-07-18 Variation Biotechnologies, Inc. Compositions et méthodes de traitement d'infections virales
WO2013111012A2 (fr) 2012-01-27 2013-08-01 Variation Biotechnologies, Inc. Procédés et compositions pour agents thérapeutiques
ES2732229T3 (es) 2012-03-23 2019-11-21 Pitney Pharmaceuticals Pty Ltd Inhibidores de cinasa para el tratamiento del cáncer
IN2014DN10408A (fr) 2012-06-05 2015-08-14 Univ Australian
NZ729555A (en) 2012-08-06 2017-08-25 Pitney Pharmaceuticals Pty Ltd Compounds for the treatment of mtor pathway related diseases
GB201218195D0 (en) 2012-10-10 2012-11-21 Istituto Zooprofilattico Sperimentale Delle Venezie Composition
US11369666B2 (en) 2012-12-17 2022-06-28 Newsouth Innovations Pty Limited Treatment of diseases involving mucin
EP3446708A1 (fr) 2012-12-24 2019-02-27 Cell Ideas Pty Ltd. Vaccins pour le traitement du cancer et compositions pour améliorer l'efficacité de vaccins
EP3016968B1 (fr) 2013-07-01 2019-06-26 Newsouth Innovations Pty Limited Diagnostic et traitement de maladies autoimmunes
US20150166255A1 (en) * 2013-12-12 2015-06-18 ASCLEMED USA, INC. dba EnovaChem Manufacturing Vitamin b-12 injection kit
WO2015160501A1 (fr) 2014-04-18 2015-10-22 Auburn University Formulations de vaccin particulaire pour induire l'immunité innée et acquise
US10293044B2 (en) 2014-04-18 2019-05-21 Auburn University Particulate formulations for improving feed conversion rate in a subject
CN116603058A (zh) 2015-03-26 2023-08-18 Gpn疫苗有限公司 链球菌疫苗
AU2018241252A1 (en) 2017-03-30 2019-10-03 The University Of Queensland Chimeric molecules and uses thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2118963T3 (es) * 1992-05-23 1998-10-01 Smithkline Beecham Biolog Vacunas combinadas, que contienen antigeno de superficie de la hepatitis b y otros antigenos.
JP3158157B2 (ja) * 1994-11-10 2001-04-23 バクスター・アクチエンゲゼルシャフト 無蛋白培養における生物製剤の製造法
FR2754715B1 (fr) * 1996-10-18 1998-11-13 Seppic Sa Adjuvant, notamment sous forme d'une emulsion contenant un cation metallique trivalent et composition vaccinale le comprenant
US5795582A (en) 1996-02-07 1998-08-18 Novavax, Inc. Adjuvant properties of poly (amidoamine) dendrimers

Also Published As

Publication number Publication date
HUP0103908A2 (hu) 2002-02-28
ES2257072T3 (es) 2006-07-16
HUP0103908A3 (en) 2003-10-28
US6372223B1 (en) 2002-04-16
EP1113816B1 (fr) 2006-01-11
DE59913046D1 (de) 2006-04-06
EP1113816A2 (fr) 2001-07-11
HK1038507A1 (en) 2002-03-22
ATE315404T1 (de) 2006-02-15
WO2000015251A2 (fr) 2000-03-23
AU763210B2 (en) 2003-07-17
JP2003523310A (ja) 2003-08-05
AU5720099A (en) 2000-04-03
NO20011282L (no) 2001-05-14
AT408615B (de) 2002-01-25
WO2000015251A3 (fr) 2000-08-24
ATA155598A (de) 2001-06-15
NO20011282D0 (no) 2001-03-14

Similar Documents

Publication Publication Date Title
DK1113816T3 (da) Influenzavirus-vaccinesammensætning
UA85536C2 (en) Viral antigens
EP1618889B8 (fr) Vaccin contre l'influenza
CY1107457T1 (el) Εμβoλιο κατa του hpv
BR9906927A (pt) Proteìnas de neisseria meningitidis
UY26555A1 (es) Composición farmacéutica para modulación inmunológica y preparación de vacunas
MY133780A (en) Vaccine composition
IS4518A (is) Nýtt lyfjaform fyrir bóluefni
DK1076566T3 (da) Svækkede mutanter af salmonella, som konstruktivt udtrykker Vi-antigenet
AU5457596A (en) Adjuvants for viral vaccines
PT745388E (pt) Composicao de vacinas para mamiferos compreendendo esqualeno ou esqualano fosfolipido e um tensioactivo como adjevante
TR200401569T4 (tr) Flagelin ya da flagelle'ya karşı antikorların oluşumuna sebep olmayan salmonelle aşısı
UA42741C2 (uk) Пептид маститної вакцини (варіанти), пептид складного антигенного представлення (варіанти), фармацевтична композиція (варіанти)
DK1401492T3 (da) LTB4 som vaccineadjuvans
WO2002032455A3 (fr) Vaccin
WO2002077648A3 (fr) Antigenes vaccinaux de nesseria pathogenes et commensaux
WO2001043769A3 (fr) Administration d'antigene
AU4537100A (en) Adjuvant combinations for immunization composition and vaccines
WO2001049320A3 (fr) Compositions pharmaceutiques et leur preparation
DK1204420T3 (da) Trehaloseproducerende prokaryotiske celler som vacciner
EA199900583A2 (ru) Композиция на основе метопролола и способы ее получения
WO2002060469A1 (fr) Agents anticancereux
NZ316110A (en) vaccine containing an antigen from H. Influenzae and an antigen from influenza virus
UA67250A (en) Strain bovinae herpesvirus-1 "moldavian" for the preparation of vaccines and diagnosticums
WO1999027955A3 (fr) Traitement d'infections chroniques etablies et de cancers